BioCentury | Oct 1, 2020
Product Development

Sept. 30 Quick Takes: $234M for NIH’s RADx-UP; plus CureVac, Allena, Covaxx

...A $25 million convertible note deal with Pontifax Medison Finance will extend the cash runway of Allena Pharmaceuticals Inc....
...from Taiwan’s Ministry of Health and Wellness to support Phase I and Phase II human trials. BC Staff NIH CureVac Allena Pharmaceuticals Covaxx COVID19 covid-19 cov19count bts20hd Pontifax cov19count...
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...director. Megaffin was president of Churchill Pharmaceuticals LLC (King of Prussia, Pa.). Metabolic disease company Allena Pharmaceuticals Inc....
BioCentury | Jan 13, 2018
Finance

Choosy investors

...two worst performers -- infectious disease manufacturer Spero Therapeutics Inc. (NASDAQ:SPRO) and kidney disease company Allena Pharmaceuticals Inc....
...N.V. (NASDAQ:IFRX) 11/8/17 $100.0 $351.2 $490.5 40% TissueGene Inc. (KOSDAQ:950160) 11/6/17 $182.3 $1,468.8 $2,817.9 92% Allena Pharmaceuticals Inc....
BioCentury | Nov 3, 2017
Financial News

Allena raises $74.7M IPO

...On Nov. 1, kidney disease company Allena Pharmaceuticals Inc. (NASDAQ:ALNA) raised $74.7 million through the sale of 5.3...
...studies in 2H19. ALLN-177 is an oral recombinant oxalate degrading enzyme. Allena Pharmaceuticals Inc. (NASDAQ:ALNA), Newton, Mass. Jennie Walters ALLN-177 Allena Pharmaceuticals Inc....
BioCentury | Nov 2, 2017
Financial News

Spero sags after $77M listing

...SPR741 in combination with a general antibiotic in 1H18 to treat cUTIs. Kidney disease company Allena Pharmaceuticals Inc....
BioCentury | Nov 2, 2017
Financial News

Allena slips after pricing $74.7M IPO

...also fell on its first day of trading on Thursday, losing $2.50 (18%) to $11.50. Jennie Walters ALLN-177 Allena Pharmaceuticals Inc....
BioCentury | Oct 13, 2017
Financial News

Allena proposes $92M IPO

...Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million on Oct. 6...
...Fidelity Management & Research Co. and HBM Healthcare Investments. Allena Pharmaceuticals Inc. , Newton, Mass. Allison Johnson ALLN-177 Ajinomoto Co. Inc. Allena Pharmaceuticals Inc. Althea...
BioCentury | Oct 9, 2017
Financial News

Allena proposes $92M IPO

...Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million in an IPO...
...Third Rock Ventures, Bessemer Venture Partners, Fidelity Management & Research Co. and HBM Healthcare Investments. Allison Johnson ALLN-177 Allena Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Finance

High as a Kite

...exchange; Source: BCIQ: BioCentury Online Intelligence Company Date filed To be raised (A) Status (B) Allena Pharmaceuticals Inc....
BioCentury | Feb 15, 2016
Clinical News

ALLN-177: Phase II started

...units of oral ALLN-177 thrice daily with meals for 28 days in about 44 patients. Allena Pharmaceuticals Inc....
Items per page:
1 - 10 of 28
BioCentury | Oct 1, 2020
Product Development

Sept. 30 Quick Takes: $234M for NIH’s RADx-UP; plus CureVac, Allena, Covaxx

...A $25 million convertible note deal with Pontifax Medison Finance will extend the cash runway of Allena Pharmaceuticals Inc....
...from Taiwan’s Ministry of Health and Wellness to support Phase I and Phase II human trials. BC Staff NIH CureVac Allena Pharmaceuticals Covaxx COVID19 covid-19 cov19count bts20hd Pontifax cov19count...
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...director. Megaffin was president of Churchill Pharmaceuticals LLC (King of Prussia, Pa.). Metabolic disease company Allena Pharmaceuticals Inc....
BioCentury | Jan 13, 2018
Finance

Choosy investors

...two worst performers -- infectious disease manufacturer Spero Therapeutics Inc. (NASDAQ:SPRO) and kidney disease company Allena Pharmaceuticals Inc....
...N.V. (NASDAQ:IFRX) 11/8/17 $100.0 $351.2 $490.5 40% TissueGene Inc. (KOSDAQ:950160) 11/6/17 $182.3 $1,468.8 $2,817.9 92% Allena Pharmaceuticals Inc....
BioCentury | Nov 3, 2017
Financial News

Allena raises $74.7M IPO

...On Nov. 1, kidney disease company Allena Pharmaceuticals Inc. (NASDAQ:ALNA) raised $74.7 million through the sale of 5.3...
...studies in 2H19. ALLN-177 is an oral recombinant oxalate degrading enzyme. Allena Pharmaceuticals Inc. (NASDAQ:ALNA), Newton, Mass. Jennie Walters ALLN-177 Allena Pharmaceuticals Inc....
BioCentury | Nov 2, 2017
Financial News

Spero sags after $77M listing

...SPR741 in combination with a general antibiotic in 1H18 to treat cUTIs. Kidney disease company Allena Pharmaceuticals Inc....
BioCentury | Nov 2, 2017
Financial News

Allena slips after pricing $74.7M IPO

...also fell on its first day of trading on Thursday, losing $2.50 (18%) to $11.50. Jennie Walters ALLN-177 Allena Pharmaceuticals Inc....
BioCentury | Oct 13, 2017
Financial News

Allena proposes $92M IPO

...Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million on Oct. 6...
...Fidelity Management & Research Co. and HBM Healthcare Investments. Allena Pharmaceuticals Inc. , Newton, Mass. Allison Johnson ALLN-177 Ajinomoto Co. Inc. Allena Pharmaceuticals Inc. Althea...
BioCentury | Oct 9, 2017
Financial News

Allena proposes $92M IPO

...Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million in an IPO...
...Third Rock Ventures, Bessemer Venture Partners, Fidelity Management & Research Co. and HBM Healthcare Investments. Allison Johnson ALLN-177 Allena Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Finance

High as a Kite

...exchange; Source: BCIQ: BioCentury Online Intelligence Company Date filed To be raised (A) Status (B) Allena Pharmaceuticals Inc....
BioCentury | Feb 15, 2016
Clinical News

ALLN-177: Phase II started

...units of oral ALLN-177 thrice daily with meals for 28 days in about 44 patients. Allena Pharmaceuticals Inc....
Items per page:
1 - 10 of 28